The main advantage and at the same time the goal of CXL is to inhibit the progression of the ectatic disease and to increase the biomechanical rigidity of the cornea. The stiffening effect produced causes a postoperative reduction of keratometry, changing the shape of the cornea. Even so, visual outcomes are remotely improved [5] and in some cases even after CXL patients cannot achieve a functional visual acuity.
In order to optimize the result of CXL, adjuvant therapies (such as INTACS or customized ablations) have been proposed to develop a technique which can treat keratoconic patients and offer them both stability and functional vision. Several studies have been published that combine CXL and refractive surgery [6, 7] targeting to both stabilization and reshaping of the corneal tissue for visual function improvement. These combined methods could improve patients visual outcomes in addition to corneal stabilization (that can be named CXL plus).
We are experiencing a major change in ophthalmic practice and we are providing our patients further solutions while improving their quality of life. This is certainly a new era in treating corneal ectatic disorders that changes drastically gold standard treatments (PKP) that were unquestionable for over half a century. CXL plus is probably the way to the future, a conflated method which might represent an actual cure for all kinds of ectatic disorders of the cornea.
